{"id":"NCT02552212","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS","officialTitle":"Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2018-05","completion":"2020-05","firstPosted":"2015-09-17","resultsPosted":"2020-08-17","lastUpdate":"2022-08-18"},"enrollment":317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Axial Spondyloarthritis","Nonradiographic Axial Spondyloarthritis","Nr-axSpA"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Certolizumab Pegol 200 mg Q2W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients.","primaryOutcome":{"measure":"Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Placebo (FAS)","deltaMin":7,"sd":null},{"arm":"CZP 200 mg Q2W (FAS)","deltaMin":47.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":105,"countries":["United States","Australia","Bulgaria","Canada","Czechia","Hungary","Poland","Russia","Taiwan"]},"refs":{"pmids":["35296532","35733363","34715908","30848558"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":158},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Arthralgia","Bronchitis"]}}